Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination

Abstract

Cardiovascular disease (CVD) is the single largest cause of mortality in patients with chronic kidney disease (CKD), with those patients having a 10-year CVD-related morbidity and mortality of > 20%. This has led to the inclusion of CKD as a CVD equivalent, and justifies the aggressive treatment of modifiable risk factors such as dyslipidemia. Primary care physicians (PCP) often manage patients with CKD in the early stages of the disease and have a pivotal role in affecting long-term outcomes in CKD patients related to cardiovascular and all-cause mortality. Therefore, treatment of dyslipidemia often becomes the responsibility of the PCP and comes with its own set of challenges because of CKD-related issues (eg, the dose adjustments required). Exacerbating this problem is the fact that current guidelines are lengthy and complex. This article discusses the current guidelines for treating dyslipidemia in patients with CKD. Few studies have examined the safety and efficacy of pharmacotherapy for treatment of dyslipidemia in the CKD population, and ongoing studies such as the Study of Heart and Renal Protection (SHARP) should help clarify the current treatment guidelines.

Keywords:

• dyslipidemia
• chronic kidney disease
• statins
• yend stage renal disease